Thermo Fisher Science公司在2025年Q3比预期收入高,提高了全年指导水平,提高了红利,而内幕人士则出售股票。 Thermo Fisher Scientific beat earnings expectations in Q3 2025, raised full-year guidance, and boosted its dividend, while insiders sold shares.

Voya投资管理、Signal Advisors和Franklin Street Advisors在2025年第三季度增持了Thermo Fisher Scientific的股份，公司报告了每股盈余579美元和收入111.2亿美元的强劲表现，超出预期。 Voya Investment Management, Signal Advisors, and Franklin Street Advisors increased their stakes in Thermo Fisher Scientific during the third quarter of 2025, with the company reporting strong earnings of $5.79 EPS and $11.12 billion in revenue, surpassing expectations. 该公司将2025财政年度的指导意见提高到每股22.60至22.86美元,而内幕人士出售了149 271股。 The firm raised its FY 2025 guidance to $22.60–$22.86 per share, while insiders sold 149,271 shares. 分析师维持“机动购买”评级,目标为616.60美元,公司宣布季度红利为4.43美元。 Analysts maintain a “Moderate Buy” rating with a $616.60 target, and the company announced a quarterly dividend of $0.43. Thermo Fisher Scientific，作为全球生命科学和诊断领域的领导者，市值为2130.3亿美元，并实行回购计划，允许最多2.4%的股份被回购。 Thermo Fisher Scientific, a global leader in life sciences and diagnostics, has a market cap of $213.03 billion and a buyback program allowing up to 2.4% of shares to be repurchased.